Live Breaking News & Updates on Boehringer Ingelheim Immunooncology T3 Pharmaceuticals Ag Pharma Cancer Treatment Michel Pairet Simon Ittig Venture Fund Acquisition

Stay updated with breaking news from Boehringer ingelheim immunooncology t3 pharmaceuticals ag pharma cancer treatment michel pairet simon ittig venture fund acquisition. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Boehringer Ingelheim expands immunooncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Boehringer Ingelheim today announced the acquisition of privatelyheld T3 Pharmaceuticals AG T3 Pharma a clinical stage Swiss biotech company for an amount of up to 450 million CHF. ....

Switzerland General , Boehringer Ingelheim , Engagers Tces , Simon Ittig , Michel Pairet , Boehringer Ingelheim Venture Fund , T Cell Engagers , Managing Directors , Media Contact , Ten Wolde , Media Relations , Boehringer Ingelheim Immunooncology T3 Pharmaceuticals Ag Pharma Cancer Treatment Michel Pairet Simon Ittig Venture Fund Acquisition ,